

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number  
**WO 2005/009464 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**

(81) Designated States (*national*): MX, US.

(21) International Application Number:  
PCT/IB2003/002971

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(22) International Filing Date: 25 July 2003 (25.07.2003)

**Published:**

(25) Filing Language: English

— with international search report

(26) Publication Language: English

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(71) Applicants and

(72) Inventors: **LÓPEZ DE SILANES, Juan** [MX/MX]; Lucerna No. 7, C.P. 06600 Col. Juárez, Delegación, Cuauhtémoc (MX). **PANIAGUA-SOLÍS, Jorge, F.** [MX/MX]; Cerrada de Arenal No. 44-9, C.P. 14600 Col. Valle Escondido Delegación Tlalpan (MX). **DIAZ-QUIÑONEZ, Alberto** [MX/MX]; Latacunga #755, C.P. 07300 Col. Lindavista Delegación Gustavo A. Madero (MX). **MANCILLA-NAVA, Rita, G.** [MX/MX]; Calzada de Tlalpan No. 4687, C.P. 14050 Col. Toriello Guerra Delegación Tlalpan (MX).

(54) Title: ADMINISTRATION OF ANTI-CYTOKINE F(AB')<sub>2</sub> ANTIBODY FRAGMENTS

(57) Abstract: The present invention is directed to a method of treating a cytokine-mediated immune reaction in a patient in need of such treatment by administration of an effective amount of anti-cytokine F(ab')<sub>2</sub> antibody fragments. The antibody fragments are preferably free from albumin and of whole antibodies, as well as substantially free of pyrogens. The anti-cytokine F(ab')<sub>2</sub> antibody fragments may be administered with an effective amount of a pharmaceutically acceptable carrier.



**WO 2005/009464 A1**